Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06682728 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
A Phase 2 study of Urothelial Carcinoma and Muscle-invasive Bladder Cancer, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT06682728: Recruiting Phase 2 study of Urothelial Carcinoma and Muscle-invasive Bladder Cancer, sponsored by University of California, Irvine.
NCT06682728 is a Phase 2 study of Urothelial Carcinoma and Muscle-invasive Bladder Cancer that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 23 participants, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06682728, a Phase 2 study of Urothelial Carcinoma and Muscle-invasive Bladder Cancer, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pathology.
Primary Outcome
To determine investigator-assessed disease-free survival (DFS) at 6 months.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Sacituzumab Govitecan (SG)
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-11-15 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
What NCT06682728 shows while recruiting
NCT06682728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT06682728 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06682728 about?
NCT06682728 is a clinical study titled "Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence". This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical path...
What is the current status of trial NCT06682728?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2024-11-15. Estimated completion is 2026-12-01.
What conditions does trial NCT06682728 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Muscle-invasive Bladder Cancer.
What interventions are being tested in trial NCT06682728?
The interventions under investigation include: Nivolumab (DRUG), Sacituzumab Govitecan (SG) (DRUG).
Who is sponsoring clinical trial NCT06682728?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06682728 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06682728's enrollment target sits among peer trials
23 69th of 85 higher than 16 of 85 other Urothelial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Circulating Tumor DNA Response In Urothelial Cancer
RECRUITING · Phase 2
-
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
RECRUITING · Phase 2
-
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI